Key result
Baseline major depressive disorder severity (HR 2.30; 95% CI 1.28-4.14) and failure to improve during treatment (HR 2.39; 95% CI 1.39-2.44) were independently associated with long-term mortality.
Why the study?
Are baseline depression severity, failure of depression to improve, and sertraline treatment associated with long-term mortality in patients with acute coronary syndrome and major depression?
Population
361 patients with acute coronary syndrome (ACS) who met criteria for major depressive disorder (MDD)
Comparison
Sertraline hydrochloride therapy for 6 months vs Placebo
Design
Cohort, randomized trial, double-blind, placebo-controlled
Follow-up
median 6.7 years
Authors
Loading...
Supports depression severity and nonresponse as mortality markers in ACS; leaves open whether treatment alters survival.
RCT (n=361)
double-blind
randomized
Are baseline depression severity, failure of depression to improve, and sertraline treatment associated with long-term mortality in patients with acute coronary syndrome and major depression?
Effect estimate: HR 2.30 (95% CI 1.28-4.14)
p-value: p=< .006
In patients with acute coronary syndrome and major depression, baseline depression severity and failure to improve over 6 months are strongly associated with increased long-term mortality, whereas 6 months of sertraline therapy itself was not associated with long-term mortality.
Glassman et al. (2009) conducted an RCT in Acute Coronary Syndrome and Major Depressive Disorder (n=361). Sertraline hydrochloride vs. Placebo was evaluated on Long-term mortality (HR 2.30, 95% CI 1.28-4.14, p=< .006). Baseline major depressive disorder severity (HR 2.30; 95% CI 1.28-4.14) and failure to improve during treatment (HR 2.39; 95% CI 1.39-2.44) were independently associated with long-term mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: